Beta Thalassemia

New England CEPAC

ICER plans to assess the comparative clinical effectiveness and value of LentiGlobin (Bluebird Bio) for the treatment of beta thalassemia. LentiGlobin is an investigational gene therapy currently marketed in Europe under the brand name Zynteglo®; an FDA decision regarding potential US approval is expected by late 2020.

Date of Review: July 2020 – NOW POSTPONED 

For questions, please contact info@icer-review.org.

Associated Meetings

July 30, 2020 10am-4pm ET

TBA


Key Dates

Associated Materials

12/05/2019 – 12/20/2019

01/06/2020

01/06/2020 – 01/27/2020

01/06/2020

02/04/2020

03/11/2020
Research Protocol

04/06/2020
Model Analysis Plan

05/27/2020
Draft Evidence Report

05/27/2020
Draft Voting Questions

05/27/2020 – 06/23/2020
Public Comments

07/16/2020
Evidence Report

07/16/2020
Revised Voting Questions

07/16/2020
Response to Public Comments

07/30/2020
Meeting Agenda

07/30/2020
Evidence Presentation

08/20/2020
Final Evidence Report and Meeting Summary

08/20/2020
Report-at-a-Glance